Search

Author/Creator Sequist, L V

1. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. (28th July 2018)

Authors:
Krug, A K; Enderle, D; Karlovich, C; Priewasser, T; Bentink, S; Spiel, A; Brinkmann, K; Emenegger, J; Grimm, D G; Castellanos-Rizaldos, E; Goldman, J W; Sequist, L V; Soria, J -C; Camidge, D R; Gadgeel, S M; Wakelee, H A; Raponi, M; Noerholm, M; Skog, J
Journal:
Annals of oncology
Issue:
Volume 29:Number 10(2018)
Page Start:
2143
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. LBA61Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). (23rd October 2018)

Authors:
Tan, D S; Kim, S-W; Sequist, L V; Ponce Aix, S; Smit, E F; Hida, T; Yang, J C-H; Felip, E; Seto, T; Grohe, C; Wolf, J; Ko, J; Marriere, E; Belli, R; Giovannini, M; Kim, D-W
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LBA2TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI. (24th November 2019)

Authors:
Han, J-Y; Sequist, L V; Ahn, M-J; Cho, B C; Yu, H; Kim, S-W; Yang, J C-H; Lee, J S; Su, W-C; Kowalski, D; Orlov, S; Cantarini, M; Verheijen, R B; Mellemgaard, A; Frewer, P; Ou, X; Oxnard, G
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search